{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:11:29Z","timestamp":1791659489842,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.rmr.2025.03.003","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:14:22Z","timestamp":1745219662000},"page":"274-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pneumopathies interstitielles diffuses induites par les anticorps conjugu\u00e9s"],"prefix":"10.1016","volume":"42","author":[{"given":"L.","family":"Maurier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-L.","family":"Ch\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pons-Tostivint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2025.03.003_bib0290","unstructured":"Couraud S, Swalduz A, Pierret T, Ranchon F, Forest F, Le Bon M, Galvaing G, Merle P, Souquet P-J, Toffart A-C, et le comit\u00e9 de r\u00e9daction des r\u00e9f\u00e9rentiels Auvergne Rh\u00f4ne-Alpes en oncologie thoracique. R\u00e9f\u00e9rentiel sur le cancer bronchique non \u00e0 petites-cellules\u00a0: actualisation 2024. ARISTOT 2024. Accessible sur http:\/\/referentiels-aristot.com\/."},{"key":"10.1016\/j.rmr.2025.03.003_bib0295","doi-asserted-by":"crossref","first-page":"e390772","DOI":"10.1200\/EDBK_390772","article-title":"Antibody-drug conjugates in gynecologic cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.rmr.2025.03.003_bib0300","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2025.03.003_bib0305","first-page":"1","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.rmr.2025.03.003_bib0310","doi-asserted-by":"crossref","first-page":"e389968","DOI":"10.1200\/EDBK_389968","article-title":"Antibody-drug conjugates for lung cancer: payloads and progress","volume":"43","author":"Rosner","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.rmr.2025.03.003_bib0315","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.rmr.2025.03.003_bib0320","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fphar.2019.00373","article-title":"The analysis of key factors related to ADCs structural design","volume":"10","author":"Tang","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0325","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.rmr.2025.03.003_bib0330","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.rmr.2025.03.003_bib0335","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rmr.2025.03.003_bib0340","doi-asserted-by":"crossref","first-page":"pkad069","DOI":"10.1093\/jncics\/pkad069","article-title":"Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis","volume":"7","author":"Suzuki","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.rmr.2025.03.003_bib0345","doi-asserted-by":"crossref","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.rmr.2025.03.003_bib0350","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.03.003_bib0355","doi-asserted-by":"crossref","first-page":"1296890","DOI":"10.3389\/fmed.2024.1296890","article-title":"Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment","volume":"11","author":"Althobiani","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.rmr.2025.03.003_bib0360","doi-asserted-by":"crossref","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.rmr.2025.03.003_bib0365","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.rmr.2025.03.003_bib0370","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.rmr.2025.03.003_bib0375","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.rmr.2025.03.003_bib0380","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jtho.2021.01.280","article-title":"OA03.03\u00a0datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2\u00a0ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01\u00a0Phase 1\u00a0study","volume":"16","author":"Spira","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0385","series-title":"Enhertu (fam-trastuzumab deruxtecan-nxki). Prescribing information","year":"2024"},{"key":"10.1016\/j.rmr.2025.03.003_bib0390","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/PPO.0000000000000630","article-title":"Antibody drug conjugates in lung cancer","volume":"28","author":"Merle","year":"2022","journal-title":"Cancer J"},{"key":"10.1016\/j.rmr.2025.03.003_bib0395","series-title":"Liste des sp\u00e9cialit\u00e9s en acc\u00e8s d\u00e9rogatoire \u2013 telisotuzumab vedotin [Internet]","year":"2023"},{"key":"10.1016\/j.rmr.2025.03.003_bib0400","unstructured":"Communiqu\u00e9 de presse\u00a0: Sanofi annonce la fin du programme \u00e9valuant le tusamitamab ravtansine apr\u00e8s qu\u2019un essai de phase III dans le traitement de 2\u00e8meligne du CBNPC n\u2019a pas atteint son crit\u00e8re d\u2019\u00e9valuation primaire [Internet] [cit\u00e9 6\u00a0octobre 2024]. Disponible sur\u00a0: https:\/\/www.sanofi.com\/fr\/media-room\/communiques-de-presse\/2023\/2023-12-21-06-30-00-2799759."},{"key":"10.1016\/j.rmr.2025.03.003_bib0405","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2\u00a0quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.rmr.2025.03.003_bib0410","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","article-title":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project","volume":"111","author":"Bubendorf","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2025.03.003_bib0415","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13000-015-0362-5","article-title":"Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?","volume":"10","author":"Watermann","year":"2015","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0420","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1038\/s41598-019-43678-6","article-title":"EGFR and HER3\u00a0expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients","volume":"9","author":"Scharpenseel","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.rmr.2025.03.003_bib0425","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.rmr.2025.03.003_bib0430","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2\u00a0antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0435","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2025.03.003_bib0440","doi-asserted-by":"crossref","first-page":"102043","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.rmr.2025.03.003_bib0445","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s10147-023-02414-x","article-title":"Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan","volume":"28","author":"Baba","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0450","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","article-title":"An Official American Thoracic Society Clinical Practice Guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.03.003_bib0455","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017."},{"key":"10.1016\/j.rmr.2025.03.003_bib0460","unstructured":"Ahn M.J., Tanaka K., Paz-Ares L., Cornelissen R., Girard N., Pons-Tostivint E., et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260\u2011272. [JCO2401544]."},{"issue":"16_suppl","key":"10.1016\/j.rmr.2025.03.003_bib0465","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1200\/JCO.2024.42.16_suppl.8617","article-title":"Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): subgroup analysis from TROPION-Lung02","volume":"42","author":"Levy","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0470","doi-asserted-by":"crossref","first-page":"S1671","DOI":"10.1016\/j.annonc.2023.10.597","article-title":"518MO TROPION-Lung05: datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)","volume":"34","author":"Kitazono","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0475","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0480","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"DESTINY-Lung01\u00a0trial investigators. trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.03.003_bib0485","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2\u00a0trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0490","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02\u00a0trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0495","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0500","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein\u00a0\u2013\u00a0overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0505","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01\u00a0study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.rmr.2025.03.003_bib0510","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1200\/JCO.2020.38.15_suppl.9505","article-title":"Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701\u00a0in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","volume":"38","author":"Gazzah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0515","series-title":"Tusamitamab ravtansine vs docetaxel in previously treated advanced nonsquamous NSCLC: results from phase 3\u00a0CARMEN-LC03\u00a0trial","author":"Besse","year":"2024"},{"key":"10.1016\/j.rmr.2025.03.003_bib0520","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.21037\/jtd.2018.05.75","article-title":"Lung cancer and interstitial lung disease: a literature review","volume":"10","author":"Naccache","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.rmr.2025.03.003_bib0525","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.03.003_bib0530","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.03.003_bib0535","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2\u00a0trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.rmr.2025.03.003_bib0540","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2022.40.6_suppl.438","article-title":"Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC)","volume":"40","author":"Galsky","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0545","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jtho.2023.09.041","article-title":"OA05.04\u00a0sacituzumab govitecan\u00a0+\u00a0pembrolizumab in 1L metastatic non-small cell lung cancer: preliminary results of the EVOKE-02\u00a0study","volume":"18","author":"Cho","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2025.03.003_bib0550","unstructured":"Merck Sharp & Dohme LLC. An Open-label, Multicenter, Phase 3\u00a0Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475\u00a0Monotherapy as First-line Treatment in Participants With PD L1\u00a0TPS Greater Than or Equal to 50\u00a0% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03) [Internet]. clinicaltrials.gov; 2024\u00a0juin [cit\u00e9 15\u00a0oct 2024]. Report No.: NCT05609968. Disponible sur\u00a0: https:\/\/clinicaltrials.gov\/study\/NCT05609968."},{"key":"10.1016\/j.rmr.2025.03.003_bib0555","unstructured":"Daiichi Sankyo. A Randomized, Open-label, Phase 3\u00a0Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-na\u00efve Subjects With Advanced or Metastatic PD-L1\u00a0High (TPS \u226550\u00a0%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) [Internet]. clinicaltrials.gov; 2024\u00a0mai [cit\u00e9 16\u00a0oct 2024]. Report No.: NCT05215340. Disponible sur\u00a0: https:\/\/clinicaltrials.gov\/study\/NCT05215340."},{"key":"10.1016\/j.rmr.2025.03.003_bib0560","unstructured":"Daiichi Sankyo. A Randomized Phase 3\u00a0Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1\u00a0TPS <50\u00a0% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) [Internet]. clinicaltrials.gov; 2024\u00a0ao\u00fbt [cit\u00e9 16\u00a0oct 2024]. Report No.: NCT05555732. Disponible sur\u00a0: https:\/\/clinicaltrials.gov\/study\/NCT05555732."},{"key":"10.1016\/j.rmr.2025.03.003_bib0565","doi-asserted-by":"crossref","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.rmr.2025.03.003_bib0285","doi-asserted-by":"crossref","first-page":"103326","DOI":"10.1016\/j.esmoop.2024.103326","article-title":"267MO Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1\u00a0interstitial lung disease\/pneumonitis (ILD)","volume":"9","author":"Rugo","year":"2024","journal-title":"ESMO Open"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842525001664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842525001664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T21:53:19Z","timestamp":1746741199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842525001664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0761842525001664"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2025.03.003","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumopathies interstitielles diffuses induites par les anticorps conjugu\u00e9s","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2025.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}